FDA Formally Rescinds Laboratory-Developed Tests Final Rule

FDA Formally Rescinds Laboratory-Developed Tests Final Rule

The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.

The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.

Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.

Sources:

https://www.reginfo.gov/public/do/eoDetails?rrid=1044563

https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf

https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

A logo with the letters 'HD' for 'HealthDay'

TELCOR POC Device Connectivity Updates - Q4 2025

TELCOR POC Device Connectivity Updates - Q4 2025

Lincoln, NE – February 17, 2026

Read More
TELCOR Inc Earns Great Place to Work® Certification for Third Consecutive Year

TELCOR Inc Earns Great Place to Work® Certification for Third Consecutive Year

Company Recognized for Ongoing Commitment to Culture, Performance, and Innovation Lincoln, Nebraska – February 16,2026 – TELCOR Inc is proud to...

Read More
Consolidated Appropriations Act Signed Into Law, Enacts One-Year Delay of CLFS Cuts

Consolidated Appropriations Act Signed Into Law, Enacts One-Year Delay of CLFS Cuts

President Donald Trump signed the Consolidated Appropriations Act of 2026 (H.R.7148) into law on Feb. 3, delaying Medicare Clinical Laboratory Fee...

Read More